Vor Biopharma (NASDAQ:VOR) Bolsa

VOR BIOPHARMA INC

Vor Biopharma

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Vor Biopharma Inc

Virgin Orbit Holdings Inc

Virgin Orbit Holdings Inc Warrants (29/12/2026)

Vornado Realty Trust

VORNADO RLTY TR 6.50 A PR by Vornado Realty Trust

Vornado Realty Trust 5.25% Series M Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share, no par value per share

Vornado Realty Trust 5.25% Series N Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share

Vornado Realty Trust 4.45% Series O Cumulative Redeemable Preferred Shares, Liquidation Preference $25.00 Per Share

Vortex Brands Co

VORTEX ENERGY CORP by Vortex Energy Corp.

Vortex Energy Corp

Vortex Energy Corp Ordinary Shares

Vortex Metals Inc

News

RELI

Reliance Global Group Highlights Spetner's Q1 Results Revenue Increased 95% YoY To ~$5.16M

HUHU

HUHUTECH International Group To Acquire 100% Of Issued Equity Interest Of Huhu Technologies Deutschland For Total Of ~$28,930

SYPR

Sypris Solutions' Sypris Technologies Enters Into Long-Term Agreement To Supply Certain Drivetrain Components For Global Truck OEM's New Electrified Heavy-Duty Vehicle

Coeptis Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the filing of a registration statement on Form S-4 with the Securities and Exchange Commission ("SEC") related to the Company's previously announced and proposed definitive merger agreement (the "Merger") with Z Squared Inc. ("Z Squared").
The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement has not yet become effective, and the information contained therein is subject to change.

COEP

Coeptis Therapeutics Files Form S-4 With SEC For Proposed Merger With Z Squared

AENT

Alliance Entertainment Partners With Master Replicas To Be Exclusive Distribution Partner

WIIM

JTAI

Jet.AI shares are trading higher after the company announced an agreement with Consensus Core to jointly develop a Phase Hyperscale data center campus in Canada.

Jet.AI  And Consensus Core Announce Agreement To Jointly Develop A Phase Hyperscale Data Center Campus In Canada

On Wednesday, the U.S. Federal Trade Commission (FTC) concluded <a href="https://www.benzinga.com/topic/antitrust">its antitrust review </a>of Mars Incorporated&#8217;s pending acquisition of Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>).
Mars is a family-owned company in the pet care, snacking, and food industries.
In August 2024, Mars agreed to acquire Kellanova for $36 billion, or <a target="_blank" href="https://www.benzinga.com/m-a/24/08/40376430/mars-to-buy-kellanova-for-36b-snickers-maker-moves-up-a-rank-on-largest-private-company-list" rel="noreferrer noopener">$83.50 per share</a>.
Poul Weihrauch, CEO &amp; Office of the President, Mars, said: &#8220;We are very pleased that the FTC has completed its review of the transaction without the imposition of any condition or requiring any remedy. The transaction has now received all but one of the 28 required regulatory clearances, with only the <a href="https://www.benzinga.com/pressreleases/25/06/b46106697/mars-pending-acquisition-of-kellanova-clears-ftc-antitrust-review" target="_blank" rel="noopener">European Commission&#8217;s review</a><a href="https://www.benzinga.com/pressreleases/25/06/b46106697/mars-pending-acquisition-of-kellanova-clears-ftc-antitrust-review" target="_blank" rel="noreferrer noopener"> outstanding</a>.
Based on the current status of the European Commission&#8217;s ongoing antitrust review, Mars and Kellanova expect the transaction to close by the end of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44961625/fda-targets-synthetic-food-dyes-in-sweeping-nutrition-overhaul" rel="noreferrer noopener">FDA Targets Synthetic Food Dyes In Sweeping Nutrition Overhaul</a>
The exact timing cannot be predicted with any certainty at this point.
On Wednesday, the European Commission <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1604" target="_blank" rel="noreferrer noopener">opened</a> an in-depth investigation to assess, under the EU Merger Regulation, Mars&#8217; proposed acquisition of Kellanova.
The Commission has preliminary concerns that the transaction could lead to higher prices for consumers due to Mars&#8217; increased negotiating power towards retailers in the European Economic Area.
As a result, Mars could use this increased leverage to, for example, extract higher prices during negotiations, which would, in turn, lead to higher prices for consumers.
The Commission has serious concerns based on these early findings:
<ul class="wp-block-list">
<li>Both companies already have a strong presence in several markets across different EU countries, partly because they sell popular brands that consumers consider essential.</li>
<li>Retailers in the European Economic Area (EEA) are worried that if Mars adds Kellanova's key brands to its lineup, it would gain even more power in negotiations. This could force retailers to agree to higher prices just to keep these must-have products on their shelves.</li>
<li>Since many shoppers prefer to do all their grocery shopping in one store, they might switch to another supermarket if their favorite brands from Mars and Kellanova aren't available.</li>
</ul>
The Commission was notified of the proposed transaction on May 16. It has 90 working days, until Oct. 31, to decide.
Kellanova reported a&nbsp;<a target="_blank" href="https://www.benzinga.com/news/25/05/45139492/kellanova-misses-q1-revenue-and-earnings-estimates-due-to-weak-global-demand-and-currency-pressure" rel="noreferrer noopener">first-quarter FY25 sales decline&nbsp;</a>of 3.6% year-on-year to $3.08 billion, missing the analyst consensus estimate of $3.18 billion.
While net sales were impacted by negative currency translation and widespread category softness, the company sustained organic growth, led again by its emerging markets.
Adjusted EPS of $0.90&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the consensus</a>&nbsp;estimate of $1.01.
Price Action: K stock is up 1.04% at $78.65 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46111863/toy-prices-see-unprecedented-surge-as-trump-tariffs-take-a-toll-theres-just-no-escaping-china" target="_blank" rel="noreferrer noopener">Toy Prices See Unprecedented Surge As Trump Tariffs Take A Toll: &#8216;There&#8217;s Just No Escaping China&#8217;</a></li>
</ul>
Photo: Shutterstock

Large Cap

General

Mars Just Got The Green Light For Its $36B Deal — But Europe Might Blow It Up

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses
Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025
IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=R7Z8sW8zFDWhFPvX3G5QLKLRU4azwr1KkAlT1kYGgC5rO_j8C7bENzeNkir0k__NRhlZOfkFnCiSI1IQITEJX8dGfUhWs1pe1bf9nAqTPXmo2EoazqPjRbdZcNb7y9B4">ReShape Lifesciences Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys.

RSLS

ReShape Lifesciences Announces Strategic Headcount Reduction; Issues Update On Merger Agreement With Vyome Therapeutics And Asset Purchase Agreement With Biorad Medisys

Dividends

Kroger's Board of Directors Raises Quarterly Dividend From $0.32 To $0.35/Share

Iran, a founding member of OPEC in 1960, <a href="https://europeancapitalinsights.substack.com/p/iran-loses-influence-in-opec-after?r=3nmatg">has lost influence</a> in the oil cartel that provides 36% of the world's production as the Islamic Republic's status eroded over decades due to sanctions and its meddling in the Middle East.
Tehran has 157 billion barrels of proven oil reserves, equivalent to approximately 12% of the global total. Iran exports just under half of its oil output to China through a shadow fleet of aging tankers.
"Iran is not a major OPEC producer any longer," Karen Young, senior fellow at the Middle East Institute, said. "The industry in Iran has suffered from a long-term lack of investment and technology."
At its peak in the 1970s, Iran pumped over 6 million barrels per day (bpd). The<a target="_blank" rel="noreferrer noopener" href="https://www.opec.org/monthly-oil-market-report.html"> OPEC monthly oil report</a> estimated May production at around 3.3 million barrels per day (bpd), out of which it was exporting 1.84 million bpd,<a target="_blank" rel="noreferrer noopener" href="https://www.eia.gov/international/content/analysis/special_topics/SHIP_Act/SHIP-Act.pdf"> mainly to China</a>.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!nbAJ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd44d260a-a773-4a4d-adb3-ded3685da310_863x417.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!nbAJ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd44d260a-a773-4a4d-adb3-ded3685da310_863x417.png" alt="" /></a><figcaption class="wp-element-caption">Iran's oil exports, 2017 vs 2024, Source: S&amp;P Global</figcaption></figure>
<a href="https://x.com/eurocapinsights/status/1938193699730510146">Sanctions have granted Iran</a> exemptions from OPEC+ quotas, but that also means it has no say in shaping the group's output policy. For example, in 2022, members ignored Tehran's call for a bloc-wide oil embargo on Israel.
Still, the Vienna-based cartel remains the best opportunity for the country to engage with the world. "Frankly speaking, OPEC is the one and only diplomatic channel for Iran," a source familiar with its participation<a target="_blank" rel="noreferrer noopener" href="https://www.spglobal.com/commodity-insights/en/news-research/latest-news/crude-oil/061725-feature-iran-diminished-in-opec-no-longer-holds-oil-trump-card"> told</a> Platts back in March.
<h2 class="wp-block-heading">Iran's Isolation Driven by Sanctions, Regional Policies</h2>
Iran's international isolation started in 1979 after the Iranian Revolution. The US, under then-President Jimmy Carter, imposed sanctions after Iranian students stormed the American embassy in Tehran, holding 66 Americans captive for a 444-day hostage crisis.
Since then, the US has imposed additional sanctions that target Iran's economy, nuclear program, and support for terrorism. In June, the Department of the Treasury <a target="_blank" rel="noreferrer noopener" href="https://home.treasury.gov/news/press-releases/sb0175">designated one</a> individual and eight entities for their involvement in the procurement and transshipment of sensitive defense-related machinery to Iran.
"The United States remains resolved to disrupt any effort by Iran to procure the sensitive, dual-use technology, components, and machinery that underpin the regime's ballistic missile, unmanned aerial vehicle, and asymmetric weapons programs," US Secretary of the Treasury Scott Bessent said. "We have been clear: those who enable these schemes will be held accountable."
The US <a target="_blank" rel="noreferrer noopener" href="https://europeancapitalinsights.substack.com/p/trump-arrives-for-nato-summit-europe">attacked Iran's</a> Fordow, Natanz, and Isfahan nuclear plants as part of that effort. The US strikes, codenamed "Operation Midnight Hammer," consisted of 14 30,000lbs GBU-57 "bunker buster" bombs deployed by US B-2 stealth bombers and around 30 Tomahawk missiles fired from US submarines.
<h2 class="wp-block-heading">Insurers Brace For Escalation in Middle East</h2>
The strikes initially sent crude oil prices 23% higher, to $79.60 per barrel, before pulling back 15% following Iran's retaliation. Markets stabilized after Trump announced on <a target="_blank" rel="noreferrer noopener" href="https://truthsocial.com/@realDonaldTrump/posts/114734934153569653">Truth Social</a> on Monday that Israel and Iran have agreed to a &#8220;complete and total ceasefire.&#8221;
Insurance markets are already reacting, assessing the risks from the Strait of Hormuz, to Houthi rebels, to Israeli ports. War risk premiums have surged, particularly for voyages to Israeli ports, where insurance rates have tripled, from 0.2% to 0.7%. The situation reflects the risks that those ports could become collateral damage or direct targets in the event of further escalation.
"We currently consider the threat to the maritime domain to be unchanged but with a negative outlook." David Osler, Lloyd's List Insurance editor, <a target="_blank" rel="noreferrer noopener" href="https://archive.is/nvM5S#selection-1245.0-1245.11">noted</a> last week.
According to a June 18<a target="_blank" rel="noreferrer noopener" href="https://www.argusmedia.com/en/news-and-insights/latest-market-news/2700473-israel-iran-conflict-raises-european-middle-distillates"> report</a> from Argus, a London-based global market analysis firm, European jet fuel and diesel prices are rising due to concerns about a potential supply shortage.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!jbpJ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb61efc62-f8b5-422b-8a8d-f33241e7d009_1306x691.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!jbpJ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb61efc62-f8b5-422b-8a8d-f33241e7d009_1306x691.png" alt="" /></a><figcaption class="wp-element-caption">Low Sulphur ICE Gasoil Futures, year-to-date. Source: TradingView</figcaption></figure>
The report also showed that front-month ICE gasoil futures jumped by a<a target="_blank" rel="noreferrer noopener" href="https://www.argusmedia.com/en/news-and-insights/latest-market-news/2700473-israel-iran-conflict-raises-european-middle-distillates"> record on the day increase</a> of $45.47/t reaching $731/t on June 17. This is the highest daily increase since the Russia-Ukraine war began in February 2022.
Tanker operators are especially wary. Spot rates for VLCCs and LR2s have doubled, and several shipowners, including Frontline, have suspended Gulf transits altogether. Iran, as a precautionary move, has asked ships to leave its ports.
<h2 class="wp-block-heading">GCC States Call for De-Escalation</h2>
While many of OPEC members have issued statements calling for de-escalation after the US strikes, many privately welcomed the US attack against the Islamic Republic. In 2008, former Saudi King Abdullah <a target="_blank" rel="noreferrer noopener" href="https://www.reuters.com/article/world/us-politics/cut-off-head-of-snake-saudis-told-us-on-iran-idUSTRE6AS02B/">called for the</a> US to &#8220;cut off the head of the snake&#8221; in relation to Iran's nuclear program.
Saudi Arabia and the United Arab Emirates, both members of OPEC, consider Iran a rival for regional dominance. Saudi Arabia, the world's largest oil supplier, and Iran have supported opposite sides of conflicts across the Middle East. Iranian-backed Houthi rebels in Yemen have attacked Saudi infrastructure and cargo shipping routes through the Red Sea.
In Syria, Saudi Arabia supported anti-Assad rebel groups, including Sunni factions like the Free Syrian Army and other Islamist groups, with funding, arms, and political backing. Iran, on the other hand, provided military support to the Assad regime until it <a target="_blank" rel="noreferrer noopener" href="https://x.com/AP/status/1865610269449240963">collapsed last year</a>.
Geopolitical rivalries have eroded Iran's role in OPEC and its international standing.
"Iran is totally isolated," ABC News contributor Steve Ganyard <a target="_blank" rel="noreferrer noopener" href="https://x.com/ABC/status/1936596258942067046">said</a>. "They have no friends, they have no allies, they have nobody that&#8217;s going to come to their aid."
<h2 class="wp-block-heading">Iranian Threat to Close Strait of Hormuz Would Alienate Tehran</h2>
Iran has also threatened to close the Strait of Hormuz, where about 20% of the world's<a target="_blank" rel="noreferrer noopener" href="https://youtu.be/JTvf790RWN0?feature=shared"> daily oil supply</a> currently passes, in retaliation for the US airstrikes. The <a target="_blank" rel="noreferrer noopener" href="https://europeancapitalinsights.substack.com/p/trump-arrives-for-nato-summit-europe">narrow passage </a>located off Iran's southern coast serves as the link between the Persian Gulf, the Gulf of Oman, and the wider Arabian Sea.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!Rtne!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd454fb86-024b-4d2b-a9e6-d3e0894dd728_1320x742.jpeg" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!Rtne!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd454fb86-024b-4d2b-a9e6-d3e0894dd728_1320x742.jpeg" alt="" /></a><figcaption class="wp-element-caption">The Strait of Hormuz. Source: <a target="_blank" rel="noreferrer noopener" href="https://www.marketwatch.com/story/strait-of-hormuz-the-worlds-biggest-oil-chokepoint-in-focus-as-us-iran-tensions-flare-2020-01-03">MarketWatch</a></figcaption></figure>
Saudi Arabia uses the strait to export around 6 million barrels of crude oil per day &#8211; more than any neighboring country &#8211; <a href="https://www.bbc.com/news/articles/c78n6p09pzno" target="_blank" rel="noreferrer noopener">according to</a> research by analytics firm Vortexa.
US Secretary of State Marco Rubio has claimed that Iran&#8217;s closure of the strait would amount to &#8220;economic suicide.&#8221; He called on China, an ally of Tehran, to intervene.
Energy analyst Vandana Hari said Iran has &#8220;little to gain and too much to lose&#8221; from closing the Strait of Hormuz. &#8220;Iran risks turning its oil and gas producing neighbors in the Gulf into enemies and invoking the ire of its key market, China, by disrupting traffic in the Strait,&#8221; Hari <a href="https://www.bbc.com/news/articles/c78n6p09pzno" target="_blank" rel="noreferrer noopener">told </a>BBC News.
Disclaimer:
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational purposes only.&nbsp;
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Eurozone

Commodities

Opinion

Trading Ideas

Insurance

Iran Loses Influence in OPEC After Years of Sanctions, Regional Meddling

Jefferies analyst Kaumil Gajrawala maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Buy and lowers the price target from $167 to $145.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Clorox, Lowers Price Target to $145

<a href="https://www.globenewswire.com/Tracker?data=aIS6GRuk4bvwZ-jhdc8agSB8lNMrO_HhwPG2Zm46lQtTjLhNm9cHkFv9m7M_Ss0NL87mnu4AmqYWASdfWQ_lmd4HtbeS_Pz94pgFS91B_SI=">Vivos Therapeutics, Inc.</a> ("Vivos" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos' patented Daytime-Nighttime Appliance (DNA).
The study importantly noted that "This is the first study demonstrating that the [Vivos DNA] device is safe and efficacious in treating children with OSA." In September 2024, Vivos received an unprecedented FDA 510(k) clearance for the DNA device to treat moderate to severe OSA in children. This latest study confirms and reinforces the safety and efficacy underlying that clearance.
In the study, 79% of patients showed OSA improvement, with 61.7% improving by 50% or more, and 17% experiencing resolution of their OSA. Ninety three percent (93%) of children in the study with severe OSA saw their symptoms decrease by at least 50%. There were no safety issues or concerns. The study examined recognized endpoints for measuring treatment of OSA, including a Pediatric Sleep Questionnaire (PSQ), apnea-hypopnea index (AHI), and intermolar width. Forty-seven participants were included in the analytic dataset following trial completion after 12–24 months.

VVOS

Vivos Therapeutics Announces European Journal Of Pediatrics Publishes Results Of Multicenter Clinical Trial Results For Treatment Of OSA In Children Using Vivos' Patented Daytime-Nighttime Appliance

Macro Economic Events

Econ #s

Economics

USA Goods Trade Balance For May. -96.59B Vs -86.30B Est.

Macro Notification

USA Initial Jobless Claims 236K Vs 244K Est.

USA Durable Goods Orders (MoM) For May 16.4% Vs 8.6% Est.

Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) is currently in its 17th phase of the 18-phase Adhishthana Cycle. While the stock&#8217;s broader structure still holds bullish potential, current positioning likely suggests a bearish move before the final rally unfolds. Here's a breakdown of what lies ahead for HLT according to the Adhishthana Principles.
<h3 class="wp-block-heading">HLT's Guna Triads and Their Implications</h3>
The Adhishthana Prinicples outline that Phases 14, 15, and 16 together form what's called the Guna Triads, a crucial segment that determines the nature of Phase 18. When these phases are driven by bullish strength (Satoguna), a clean upward move is likely in Phase 18. However, if they end with bearish energy (Tamoguna), the final phase typically opens with what's referred to as a "death move."
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="537" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26094414/HLT-Adhishthana.png" alt="Fig.1 HLT Guna Triads (Source: Adhishthana.com)" class="wp-image-14919" style="width:637px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26094414/HLT-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26094414/HLT-Adhishthana-300x134.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26094414/HLT-Adhishthana-1024x458.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26094414/HLT-Adhishthana-768x344.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 HLT&#8217;s Guna Triads (Source: Adhishthana.com)</figcaption></figure>
In HLT's case, Phases 14 and 15 were both driven by mild Satoguna, with rallies of roughly 23% and 26%, respectively. But Phase 16 introduced a severe Tamoguna, pushing the stock down nearly 28%. This change in energy marks a sharp departure from the ideal path toward a clean Nirvana move.
Quoting from my book, Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"If the Gūna Triad concludes with a strong Tamoguna in C16, C18 will begin with a decisive death move."
</blockquote>
Given this setup, Phase 18 for HLT is expected to begin with a significant bearish move before any substantial upside can materialize.
<h3 class="wp-block-heading">Outlook for Phase 18: A Final Shakeout Before Nirvana</h3>
HLT is currently in Phase 17, which is generally considered a no-action phase within the Adhishthana framework. This phase is marked by low conviction. It continues until November 9, 2025.&nbsp;
Once the stock transitions into Phase 18 on November 10, 2025, the framework suggests a bearish &#8220;death move&#8221; will likely begin. This move is expected to unfold between 10 November 2025 and 10 May 2026, during which the stock could experience a sharp correction driven by residual Tamoguna.
Only after this death move concludes is the stock expected to stabilize and begin its final rally, potentially leading to new all-time highs. This Satoguna-driven rebound typically represents the last major opportunity for investors to capture upside before the cycle resets.&nbsp;
<h3 class="wp-block-heading">Investor Takeaway for HLT: Stay Patient</h3>
Despite HLT's overall bullish long-term structure, the near-term outlook remains weak. The presence of a strong Tamoguna in the Guna Triads, along with the inertia of Phase 17, indicates that a breakdown is more likely than a breakout in the coming months. The best course of action is to remain on the sidelines until the death move in Phase 18 is complete. A more favorable risk-reward setup will likely emerge sometime after May 2026, once the final phase's early turbulence has passed.

Equities

Technicals

Signals

HLT Stock: A Breakdown Likely Before It Hits All-Time Highs

PRSO

Peraso shares are trading higher after the company announced an unsolicited non-binding proposal to acquire Peraso in an all-stock deal.

Core PCE Prices (Q1) 3.5% vs +3.4% Est.

USA PCE Prices For (Q1) 3.7% Vs 3.6% Est.

Financing

Press Releases

Vor Bio Announces $55.6 Million Private Placement

Management

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Health Care

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Earnings

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

PureTech Announces Annual Results for Year Ended December 31, 2024

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces $175 Million Private Placement

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

PRTC

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Cibus

CervoMed

Cue Biopharma

Elutia

Forte Biosciences

IGM Biosciences

Immix Biopharma

Immunic

MediciNova

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pyxis Oncology

Renovaro

Repare Therapeutics

Serina Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Surrozen

Sutro Biopharma

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Zura Bio Limited - Class A Ordinary shares

Zura Bio

JMP Securities

Oppenheimer

Stifel

Baird

Barclays

Vor Biopharma shares are trading higher after the company announced it signed a global license agreement with Remegen for its autoimmune asset telitacicept.

Comments

Vor Biopharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL